According to the latest news from Reuters, Belviq, a slimming drug produced by Arena Pharmaceutical Factory in the United States, was rejected by the FDA on 20 10 on the grounds that it had doubts about tumor formation in animal experiments. The pharmaceutical factory later supplemented the results of human experiments, which proved that there was no doubt, so it passed the test. It is expected that 20 13 will be officially listed in the United States.
The FDA officially approved the marketing of Belviq, the second oral diet drug. This alternative "blue pill" is definitely a great boon for people who want to lose weight easily. (Photo/taken from BBC in the UK) According to the report released by the FDA, Belviq will not "activate" the chemicals that cause heart disease, but "find another way" to let the brain release information that reduces appetite or satiety in advance, thus reducing food intake and weight accordingly.
In the human experiment of Arena Pharmaceutical Factory, after taking Belviq for one year, the average weight of the subjects decreased by about 3% to 3.7%, and 47% patients without diabetes could even lose 5%. The effect is relatively mild, but it has reached the standard stipulated by FDA. However, if the subject does not lose 5% of the expected weight after taking it for 3 months, it means that the drug has not played its due role, and continued consumption may harm the body, so the drug should be stopped immediately.
The United States is the world's leading "obesity country", with up to 35% of the population suffering from morbid obesity. It is impossible for these people with body mass index over 30 to control their diet and exercise, so the demand for oral diet pills is quite large. 1997, FDA sent a letter to ban the sale of a popular diet drug "Fenfen" because long-term use will cause damage to heart valves and the probability of heart attack will soar.